Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients -

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
Information type: Randomised controlled trials
Source: New England Journal of Medicine
Specialities: Cardiovascular system disorders
Summary
This paper reports the results from two studies of bococizumab in patients with high cardiovascular risk (either primary or secondary prevention; LDL cholesterol levels ≥1.8 or 2.6mmol/L), that were stopped prematurely following the decision to discontinue its development.
UKMi comment
Development of bococizumab, a humanized monoclonal antibody binding proprotein convertase subtilisin kexin type 9 (PCSK9), was discontinued by Pfizer in November 2016. Please see the related summary on the Specialist Pharmacy Service website for further information (link below).
Related links: SPS website